Showing results (71-80 of 132) with videos related to
Sort By:
Pageof 14
Journal of Gastroenterology|August 14, 2025
Current status of waitlist mortality and transplant probability for adult candidates with chronic end-stage liver disease for deceased donor liver transplantation under the Model for End-Stage Liver Disease score-based allocation policy in JapanYusuke Takemura, Yoshihide Ueda, Ryo Takemura, et al.British Journal of Cancer|September 15, 2023
Histological diagnosis of polyploidy discriminates an aggressive subset of hepatocellular carcinomas with poor prognosisTakanori Matsuura, Yoshihide Ueda, Yoshiyuki Harada, et al.Journal of Cancer Research and Clinical Oncology|November 22, 2020
Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancersAtsushi Yamamoto, Yoshihiko Yano, Yoshihide Ueda, et al.Biochemical and Biophysical Research Communications|January 24, 2006
Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytesYuichi Tanaka, Hiroyuki Marusawa, Hiroshi Seno, et al.Transplantation|October 26, 2013
Chronic rejection associated with antiviral therapy for recurrent hepatitis C after living-donor liver transplantationYoshihide Ueda, Toshimi Kaido, Takashi Ito, et al.Journal of Gastroenterology|June 1, 2022
Allograft liver failure awaiting liver transplantation in JapanTakuya Genda, Takafumi Ichida, Eiji Tanaka, et al.Clinical Journal of Gastroenterology|March 2, 2021
Beta-catenin-activated hepatocellular adenoma in a maleRyosuke Ishida, Yoshihiko Yano, Atsushi Yamamoto, et al.Plos One|October 4, 2011
Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencingAkihiro Nasu, Hiroyuki Marusawa, Yoshihide Ueda, et al.Anticancer Research|February 27, 2022
Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular CarcinomaShohei Komatsu, Yoshihiko Yano, Yoshimi Fujishima, et al.Journal of Gastroenterology|February 27, 2019
Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experienceYoshihide Ueda, Tsuyoshi Kobayashi, Toru Ikegami, et al.Pageof 14